scholarly journals Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis

2021 ◽  
Author(s):  
David L Kaplan ◽  
Brian L Ung ◽  
Corey Pelletier ◽  
Chuka Udeze ◽  
Ibrahim Khilfeh ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Real World ◽  
Tumor Necrosis ◽  
Claims Data ◽  
Tumor Necrosis Factor Inhibitor ◽  
Total Cost ◽  
Factor Inhibitor ◽  
Treatment Data ◽  
Necrosis Factor

Aim: Real-world treatment data for psoriatic arthritis are limited. We evaluated switch rates, adherence, and costs for patients initiating apremilast versus tumor necrosis factor inhibitor (TNFi) and interleukin inhibitor (ILi) among biologic-naive psoriatic arthritis patients. Materials & methods: This retrospective analysis used IBM MarketScan claims data to assess treatment switches, adherence and costs. Results: Twelve-month switch rates were significantly lower for apremilast versus TNFi (15.5% vs 26.6%; p < 0.0001) and similar to ILi (15.5% vs 14.0%; p = 0.71). Apremilast initiators had lower total costs versus TNFi and ILi (US$39,854 vs US$57,243 and US$65,687; p < 0.05) and adherence was slightly lower versus TNFi and higher versus ILi. Conclusion: Biologic-naive apremilast initiators had lower switch rates versus TNFi initiators and lower total costs versus TNFi or ILi initiators.

Impact of Comorbidities on Tumor Necrosis Factor Inhibitor Therapy in Psoriatic Arthritis: A Population-Based Cohort Study

2018 ◽  
Vol 70 (4) ◽  
pp. 592-599 ◽  
Author(s):  
Christine Ballegaard ◽  
Pil Højgaard ◽  
Lene Dreyer ◽  
René Cordtz ◽  
Tanja Schjødt Jørgensen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitor ◽  
Population Based ◽  
Inhibitor Therapy ◽  
Factor Inhibitor ◽  
Necrosis Factor

Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases

2020 ◽  
Vol 48 (1) ◽  
pp. 48-57
Author(s):  
Matthew L. Thomas ◽  
Gavin Shaddick ◽  
Rachel Charlton ◽  
Charlotte Cavill ◽  
Richard Holland ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Tumor Necrosis Factor ◽  
Combination Therapy ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Inhibitor ◽  
Rate Of Change ◽  
Drug Survival ◽  
Significant Difference ◽  
Factor Inhibitor ◽  
Necrosis Factor

Objective.To investigate whether tumor necrosis factor inhibitor (TNFi) combination therapy with conventional synthetic disease-modifying antirheumatic drugs (csDMARD) is more effective for psoriatic arthritis (PsA) and/or improves TNFi drug survival compared to TNFi monotherapy.Methods.Five PsA biologics cohorts were investigated between 2000 and 2015: the ATTRA registry (Czech Republic); the Swiss Clinical Quality Management PsA registry; the Hellenic Registry of Biologics Therapies (Greece); the University of Bari PsA biologics database (Italy); and the Bath PsA cohort (UK). Drug persistence was analyzed using Kaplan-Meier and equality of survival using log-rank tests. Comparative effectiveness was investigated using logistic regression with propensity scores. Separate analyses were performed on (1) the combined Italian/Swiss cohorts for change in rate of Disease Activity Score in 28 joints (DAS28); and (2) the combined Italian, Swiss, and Bath cohorts for change in rate of Health Assessment Questionnaire (HAQ).Results.In total, 2294 patients were eligible for the drug survival analysis. In the Swiss (P = 0.002), Greek (P = 0.021), and Bath (P = 0.014) databases, patients starting TNFi in combination with methotrexate had longer drug survival compared to monotherapy, while in Italy the monotherapy group persisted longer (P = 0.030). In eligible patients from the combined Italian/Swiss dataset (n = 1056), there was no significant difference between treatment arms in rate of change of DAS28. Similarly, when also including the Bath cohort (n = 1205), there was no significant difference in rate of change of HAQ.Conclusion.Combination therapy of a TNFi with a csDMARD does not appear to affect improvement of disease activity or HAQ versus TNFi monotherapy, but it may improve TNFi drug survival.

Sign in / Sign up

Export Citation Format

Share Document